Liver Research最新文献

{"title":"Resmetirom: Breakthrough therapeutic approach for metabolic dysfunction-associated steatohepatitis","authors":"Anzel Saeed, Kuldeep Dalpat Rai, Muzammil Saeed","doi":"10.1016/j.livres.2024.07.002","DOIUrl":"10.1016/j.livres.2024.07.002","url":null,"abstract":"","PeriodicalId":36741,"journal":{"name":"Liver Research","volume":"8 3","pages":"Pages 193-194"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141714982","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-term hepatitis B surface antigen kinetics after nucleos(t)ide analog discontinuation in patients with noncirrhotic chronic hepatitis B","authors":"Lina Wu ,&nbsp;Jiadi Lai ,&nbsp;Qiumin Luo ,&nbsp;Yeqiong Zhang ,&nbsp;Chaoshuang Lin ,&nbsp;Dongying Xie ,&nbsp;Youming Chen ,&nbsp;Hong Deng ,&nbsp;Zhiliang Gao ,&nbsp;Liang Peng ,&nbsp;Wenxiong Xu","doi":"10.1016/j.livres.2024.07.001","DOIUrl":"10.1016/j.livres.2024.07.001","url":null,"abstract":"<div><h3>Background and aim</h3><div>Few studies have reported hepatitis B surface antigen (HBsAg) kinetics after nucleos(t)ide analog (NA) discontinuation in patients with noncirrhotic chronic hepatitis B (CHB). The study specifically investigated long-term HBsAg kinetics after NA discontinuation.</div></div><div><h3>Methods</h3><div>Between January 2014 to January 2024, this study prospectively enrolled 106 outpatients with noncirrhotic CHB who met the discontinuation criteria after NA consolidation treatment. Demographic, clinical, and laboratory data were collected and analyzed after NA discontinuation.</div></div><div><h3>Results</h3><div>Ninety-six patients who finished 5 years of follow-up were included. HBsAg remained undetectable in 29 patients with end of treatment (EOT) HBsAg negativity. Among 67 patients with EOT HBsAg positivity, HBsAg seroclearance occurred in 12 (17.9%) patients with an estimated annual incidence of HBsAg seroclearance of 3.6%. Patients with EOT HBsAg levels of ≤1000 IU/mL had a higher HBsAg seroclearance rate than those with EOT HBsAg levels of &gt;1000 IU/mL (33.3% <em>vs</em>. 5.4%). The proportion of patients with HBsAg ≤1000 IU/mL increased during follow-up. Logistic regression analysis indicated that the EOT HBsAg level was an independent factor for HBsAg seroclearance and an HBsAg level decline exceeding 1 log10 IU/mL. The optimal EOT HBsAg cutoff for both HBsAg seroclearance and an HBsAg level decline exceeding 1 log10 IU/mL was 359 IU/mL.</div></div><div><h3>Conclusions</h3><div>Patients with EOT HBsAg negativity experienced no relapse and maintained HBsAg seroclearance during 5 years of follow-up after NA discontinuation. A higher HBsAg seroclearance rate can be obtained in patients with EOT HBsAg levels of ≤1000 IU/mL during 5 years of follow-up after NA discontinuation. Close monitoring and proper NA retreatment are recommended to guarantee the safety of NA discontinuation.</div></div><div><h3>Clinical trial number</h3><div><span><span>Clinicaltrials.gov</span><svg><path></path></svg></span> number NCT02883647.</div></div>","PeriodicalId":36741,"journal":{"name":"Liver Research","volume":"8 3","pages":"Pages 179-187"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141690926","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Portal vein tumor thrombosis in hepatocellular carcinoma patients: Is it the end?","authors":"Walaa Abdelhamed ,&nbsp;Hend Shousha ,&nbsp;Mohamed El-Kassas","doi":"10.1016/j.livres.2024.09.002","DOIUrl":"10.1016/j.livres.2024.09.002","url":null,"abstract":"<div><div>Hepatocellular carcinoma (HCC) is the sixth most prevalent form of cancer globally and the third leading cause of cancer-related mortality. The incidence of portal vein tumor thrombosis (PVTT) in HCC patients is 21% at one year and 46% at three years. The presence of PVTT has consistently been associated with a poor prognosis for HCC patients over the past decades. Notably, HCC prognosis is influenced not only by the presence of PVTT but also by the degree or extent of PVTT. Currently, there is a lack of global consensus or established protocols regarding the optimal management of HCC with associated PVTT. The Barcelona Clinic for Liver Cancer classifies HCC patients with PVTT as stage C, indicating an advanced stage, and limiting treatment recommendations for these patients to systemic therapy. In recent years, there has been an increase in the availability of therapeutic options for HCC patients with PVTT. Treatment modalities include systemic therapy, transarterial chemoembolization, surgical resection, stereotactic body radiotherapy, transarterial radioembolization, and liver transplantation. An ideal therapy for each patient necessitates a multidisciplinary approach. This review article presents the latest updates in managing HCC patients with PVTT.</div></div>","PeriodicalId":36741,"journal":{"name":"Liver Research","volume":"8 3","pages":"Pages 141-151"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142358631","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Liver-specific glucocorticoid action in alcoholic liver disease: Study of glucocorticoid receptor knockout and knockin mice","authors":"Yazheng Wang,&nbsp;Conor Fahy,&nbsp;Hong Lu","doi":"10.1016/j.livres.2024.06.001","DOIUrl":"10.1016/j.livres.2024.06.001","url":null,"abstract":"<div><h3>Background and aim</h3><p>Glucocorticoids are the only first-line drugs for severe alcoholic hepatitis (AH), with limited efficacy and various side effects on extrahepatic tissues. Liver-targeting glucocorticoid therapy may have multiple advantages over systemic glucocorticoid for AH. The aim of this study was to determine the role of hepatocellular glucocorticoid receptor (GR) in alcohol-associated steatosis (AS) and AH.</p></div><div><h3>Materials and methods</h3><p>AS was induced by a high-fat diet plus binge alcohol in adult male and female mice with liver-specific knockout (LKO) and heterozygote of GR. AH was induced by chronic-plus-binge in middle-aged male mice with liver-specific knockin of GR. Changes in hepatic mRNA and protein expression were determined by quantitative real-time polymerase chain reaction and Western blot.</p></div><div><h3>Results</h3><p>GR-LKO aggravated steatosis and decreased hepatic expression and circulating levels of albumin in both genders of AS mice but only increased markers of liver injury in male AS mice. Marked steatosis in GR-LKO mice was associated with induction of lipogenic genes and down-regulation of bile acid synthetic genes. Hepatic protein levels of GR, hepatocyte nuclear factor 4 alpha, and phosphorylated signal transducer and activator of transcription 3 were gene-dosage-dependently decreased, whereas that of lipogenic ATP citrate lyase was increased in male GR heterozygote and LKO mice. Interestingly, hepatic expression of estrogen receptor alpha (ERα) was induced, and the essential estrogen-inactivating enzyme sulfotransferase 1e1 was gene-dosage-dependently down-regulated in GR heterozygote and knockout AS mice, which was associated with induction of ERα-target genes. Liver-specific knockin of GR protected against liver injury and steatohepatitis in middle-aged AH mice.</p></div><div><h3>Conclusions</h3><p>Hepatic GR deficiency plays a crucial role in the pathogenesis of AS induced by high-fat diet plus binge, and liver-specific overexpression/activation of GR protects against chronic-plus-binge-induced AH in middle-aged mice. Hepatocellular GR is important for protection against AS and AH.</p></div>","PeriodicalId":36741,"journal":{"name":"Liver Research","volume":"8 2","pages":"Pages 91-104"},"PeriodicalIF":0.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2542568424000205/pdfft?md5=e4fec752111b323ab3a04da91784f562&pid=1-s2.0-S2542568424000205-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141414252","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hepatitis B virus as a risk factor for hepatocellular carcinoma: There is still much work to do","authors":"Walaa Abdelhamed ,&nbsp;Mohamed El-Kassas","doi":"10.1016/j.livres.2024.05.004","DOIUrl":"10.1016/j.livres.2024.05.004","url":null,"abstract":"<div><p>Hepatitis B virus (HBV) infection is a significant health problem that can result in progression to liver cirrhosis, decompensation, and the development of hepatocellular carcinoma (HCC). On a country level, the prevalence of chronic HBV infection varies between 0.1% and 35.0%, depending on the locality and the population being investigated. One-third of all liver cancer fatalities worldwide are attributable to HBV. The adoption of standard birth-dose immunization exerted the most significant impact on the decline of HBV prevalence. HCC incidence ranges from 0.01% to 1.40% in noncirrhotic patients and from 0.9% to 5.4% annually, in the settings of liver cirrhosis. Although antiviral therapy significantly reduces the risk of developing HBV-related HCC, studies have demonstrated that the risk persists, and that HCC screening is still essential. This review discusses the complex relationship between HBV infection and HCC, recent epidemiological data, different aspects of clinical disease characteristics, and the impact of antiviral therapy in this context.</p></div>","PeriodicalId":36741,"journal":{"name":"Liver Research","volume":"8 2","pages":"Pages 83-90"},"PeriodicalIF":0.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2542568424000199/pdfft?md5=d802d7bd2e6321fa394f3007326cb461&pid=1-s2.0-S2542568424000199-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141281964","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Plasma microRNA-15a/16-1-based machine learning for early detection of hepatitis B virus-related hepatocellular carcinoma","authors":"Huan Wei ,&nbsp;Songhao Luo ,&nbsp;Yanhua Bi ,&nbsp;Chunhong Liao ,&nbsp;Yifan Lian ,&nbsp;Jiajun Zhang ,&nbsp;Yuehua Huang","doi":"10.1016/j.livres.2024.05.003","DOIUrl":"10.1016/j.livres.2024.05.003","url":null,"abstract":"<div><h3>Background and aims</h3><p>Hepatocellular carcinoma (HCC), which is prevalent worldwide and has a high mortality rate, needs to be effectively diagnosed. We aimed to evaluate the significance of plasma microRNA-15a/16-1 (miR-15a/16) as a biomarker of hepatitis B virus-related HCC (HBV-HCC) using the machine learning model. This study was the first large-scale investigation of these two miRNAs in HCC plasma samples.</p></div><div><h3>Methods</h3><p>Using quantitative polymerase chain reaction, we measured the plasma miR-15a/16 levels in a total of 766 participants, including 74 healthy controls, 335 with chronic hepatitis B (CHB), 47 with compensated liver cirrhosis, and 310 with HBV-HCC. The diagnostic performance of miR-15a/16 was examined using a machine learning model and compared with that of alpha-fetoprotein (AFP). Lastly, to validate the diagnostic efficiency of miR-15a/16, we performed pseudotemporal sorting of the samples to simulate progression from CHB to HCC.</p></div><div><h3>Results</h3><p>Plasma miR-15a/16 was significantly decreased in HCC than in all control groups (<em>P</em> &lt; 0.05 for all). In the training cohort, the area under the receiver operating characteristic curve (AUC), sensitivity, and average precision (AP) for the detection of HCC were higher for miR-15a (AUC = 0.80, 67.3%, AP = 0.80) and miR-16 (AUC = 0.83, 79.0%, AP = 0.83) than for AFP (AUC = 0.74, 61.7%, AP = 0.72). Combining miR-15a/16 with AFP increased the AUC to 0.86 (sensitivity 85.9%) and the AP to 0.85 and was significantly superior to the other markers in this study (<em>P</em> &lt; 0.05 for all), as further demonstrated by the detection error tradeoff curves. Moreover, miR-15a/16 impressively showed potent diagnostic power in early-stage, small-tumor, and AFP-negative HCC. A validation cohort confirmed these results. Lastly, the simulated follow-up of patients further validated the diagnostic efficiency of miR-15a/16.</p></div><div><h3>Conclusions</h3><p>We developed and validated a plasma miR-15a/16-based machine learning model, which exhibited better diagnostic performance for the early diagnosis of HCC compared to that of AFP.</p></div>","PeriodicalId":36741,"journal":{"name":"Liver Research","volume":"8 2","pages":"Pages 105-117"},"PeriodicalIF":0.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2542568424000187/pdfft?md5=1f363a82844e27afef2899a66bb34c27&pid=1-s2.0-S2542568424000187-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141131450","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Early plasma exchange and continuous renal replacement therapy improve puerperal prognosis in hepatitis B virus-related acute-on-chronic liver failure in pregnancy","authors":"Lijuan Li,&nbsp;Mingming Fan,&nbsp;Mi Zhou,&nbsp;Pinglan Lu,&nbsp;Jianrong Liu,&nbsp;Huimin Yi,&nbsp;Xuxia Wei","doi":"10.1016/j.livres.2024.06.003","DOIUrl":"10.1016/j.livres.2024.06.003","url":null,"abstract":"<div><h3>Background and aim</h3><p>Hepatitis B virus (HBV)-related gestational acute-on-chronic liver failure (ACLF) is a severe condition with limited treatment options. This study aimed to evaluate the efficacy and ideal timing of plasma exchange and continuous renal replacement therapy (CRRT) in managing pregnant women with HBV-related ACLF.</p></div><div><h3>Methods</h3><p>This study retrospectively analyzed 51 eligible patients with HBV-related gestational ACLF between 2009 and 2020. Patients admitted to the study were divided into a conventional treatment group and a new treatment group according to whether they received the new management protocol, which included more aggressive plasma exchange (PE) and CRRT strategies. All 19 pregnant women with hepatic encephalopathy (HE) were divided into an early treatment group and a non-early treatment group according to whether PE therapy was initiated within three days. Our study had two primary objectives. Firstly, we aimed to evaluate the impact of PE and CRRT on puerperal survival. Secondly, we sought to assess the effects of early PE and CRRT regimens on puerperal survival in women with HE.</p></div><div><h3>Results</h3><p>The levels of total bilirubin on the second day postpartum (D3), the third day postpartum (D4), and the fifth day postpartum (D6) were significantly lower in the new treatment group compared to the conventional treatment group (<em>P</em> = 0.02, 0.01, and 0.02, respectively). The ALT of D3 was significantly elevated in the new treatment group compared to the conventional treatment group (<em>P</em> = 0.02). The incidence of HE overall increased from prenatal to postpartum D4, peaked on D4, and then gradually decreased from the fourth day postpartum (D5) （<em>P</em> = 0.027）. The first week after delivery revealed a significant difference in survival rate between the two groups, the conventional treatment group had statistically higher mortality rates compared to the new treatment group (<em>P</em> = 0.002). Similarly, the entire puerperal period mortality rate of the conventional treatment group was statistically higher than the new treatment group (<em>P</em> = 0.002). Moreover, among all patients with HE, the non-early treatment group showed significantly higher puerperal mortality rates compared to the early treatment group (<em>P</em> = 0.006).</p></div><div><h3>Conclusions</h3><p>Early PE and CRRT conducted within three days post-childbirth, enhance puerperal prognosis for HBV-related gestational ACLF.</p></div>","PeriodicalId":36741,"journal":{"name":"Liver Research","volume":"8 2","pages":"Pages 118-126"},"PeriodicalIF":0.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2542568424000229/pdfft?md5=7ea33d0a0647910d804af90293985ebd&pid=1-s2.0-S2542568424000229-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141410246","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Chinese expert consensus on refined diagnosis, treatment, and management of advanced primary liver cancer (2023 edition)","authors":"Xiufeng Liu ,&nbsp;Feng Xia ,&nbsp;Yue Chen ,&nbsp;Huichuan Sun ,&nbsp;Zhengqiang Yang ,&nbsp;Bo Chen ,&nbsp;Ming Zhao ,&nbsp;Xinyu Bi ,&nbsp;Tao Peng ,&nbsp;Aizier Ainiwaer ,&nbsp;Zhiwen Luo ,&nbsp;Fusheng Wang ,&nbsp;Yinying Lu ,&nbsp;National Clinical Research Center for Infectious Diseases,&nbsp;Society of Hepatology, Beijing Medical Association,&nbsp;Translational Medicine Branch,&nbsp;China Association of Gerontology and Geriatrics","doi":"10.1016/j.livres.2024.05.001","DOIUrl":"https://doi.org/10.1016/j.livres.2024.05.001","url":null,"abstract":"<div><p>Hepatocellular carcinoma (HCC), commonly known as primary liver cancer, is a major cause of malignant tumors and cancer-related deaths in China, accounting for approximately 85% of all cancer cases in the country. Several guidelines have been used to diagnose and treat liver cancer. However, these guidelines provide a broad definition for classifying advanced liver cancer, with an emphasis on a singular approach, without considering treatment options for individual patients. Therefore, it is necessary to establish a comprehensive and practical expert consensus, specifically for China, to enhance the diagnosis and treatment of HCC using the Delphi method. The classification criteria were refined for Chinese patients with HCC, and the corresponding optimal treatment regimen recommendations were developed. These recommendations took into account various factors, including tumor characteristics, vascular tumor thrombus grade, distant metastasis, liver function status, portal hypertension, and the hepatitis B virus replication status of patients with primary HCC, along with treatment prognosis. The findings and recommendations provide detailed, scientific, and reasonable individualized diagnosis and treatment strategies for clinicians.</p></div>","PeriodicalId":36741,"journal":{"name":"Liver Research","volume":"8 2","pages":"Pages 61-71"},"PeriodicalIF":0.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2542568424000163/pdfft?md5=65238cf8a759d85a68fa46f409b307fd&pid=1-s2.0-S2542568424000163-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141482147","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Generative AI: A transformative force in advancing research and care in metabolic dysfunction-associated fatty liver disease","authors":"Partha Pratim Ray","doi":"10.1016/j.livres.2024.05.002","DOIUrl":"10.1016/j.livres.2024.05.002","url":null,"abstract":"","PeriodicalId":36741,"journal":{"name":"Liver Research","volume":"8 2","pages":"Pages 127-129"},"PeriodicalIF":0.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2542568424000175/pdfft?md5=72cb71a33ad53ab396453fd192d25bf7&pid=1-s2.0-S2542568424000175-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141136377","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Role of immune cell interactions in alcohol-associated liver diseases","authors":"Xianda Wang ,&nbsp;Juan Wang ,&nbsp;Haodong Peng ,&nbsp;Li Zuo ,&nbsp;Hua Wang","doi":"10.1016/j.livres.2024.06.002","DOIUrl":"10.1016/j.livres.2024.06.002","url":null,"abstract":"<div><p>Research on inflammatory response, liver injury, and immune regulation has demonstrated that the intricate interactions among immune cells constitute a critical regulatory network. Alcohol consumption alters the liver microenvironment, triggering inflammation and immune responses. Elucidating the inhibitory, cooperative, and synergistic effects among lymphocytes and myeloid cells may reveal the core mechanisms of alcohol-associated liver disease (ALD) pathogenesis and identify promising therapeutic targets. This review seeks to elucidate the intricate and multifaceted interactions among immune cells, encompassing both direct cellular interactions and the secretion of various effector molecules. It is essential to underscore that these interactions have broader and more complex roles in ALD than the activities of individual immune cell types. These interactions play a crucial role in mutually regulating one another, thereby preserving the homeostasis of the inflammatory and immune response in the liver environment. Targeting these immune cell interactions is anticipated to offer a novel approach to the prevention and treatment of ALD.</p></div>","PeriodicalId":36741,"journal":{"name":"Liver Research","volume":"8 2","pages":"Pages 72-82"},"PeriodicalIF":0.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2542568424000217/pdfft?md5=d0bfb0849b65a5d05ca91b0d3640b151&pid=1-s2.0-S2542568424000217-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141398510","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}